Outcome of Board meeting under SEBI (Listing Obligation and Disclosure requirements) Regulations 2015 (Listing Regulations)
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.9 pts less than Nifty Microcap 250 and 9.1 pts less than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Medplus Health Services reported consolidated revenue from operations of Rs. 18,796 million for Q1 FY27 (quarter ended June 30, 2026), up about 22% from Rs. 15,426 million in Q1 FY26, driven by growth in both the Retail (Rs. 18,424 million) and Diagnostic Services (Rs. 371 million) segments. Despite strong top-line growth, consolidated net profit fell roughly 22% YoY to Rs. 331.67 million from Rs. 423.43 million, and EBITDA margins compressed due to higher depreciation and employee costs. Standalone results were healthier, with PAT up about 29% to Rs. 174.51 million. The Board also approved two CAPEX plans: a ~Rs. 400 million Food Park (including a cold-press oil extraction unit) at Hyderabad through Optival Health Solutions, and a ~Rs. 1,150 million Concierge Health & Wellness facility, signalling expansion into adjacent businesses. Additionally, Mr. Shrenik Soni was appointed as Company Secretary and Compliance Officer effective July 21, 2026. Auditor B S R and Co issued an unmodified limited review report.
Shareholders may see mixed sentiment — strong revenue growth shows healthy store/network expansion, but the sharp drop in profitability and margin compression could weigh on the stock in the short term. The sizeable CAPEX commitments (over Rs. 1.5 billion combined) signal an aggressive diversification push but will increase capital intensity and possibly pressure near-term returns.